Asset profile
Pemigatinib
Small molecule
Evidence outlook · lead readout
NCT05253807 · Non-Small Cell Lung Cancer (NSCLC)
The reported results come from study designs that frequently fail to replicate under controlled conditions — see the rationale below.
NCT05253807: This was a nonrandomized, open-label, single-arm study with no placebo or active comparator and only 8 participants, far fewer than the approximately 125 planned. The primary endpoint was clinical tumor response by RECIST, but there was no controlled comparison or formal primary-endpoint significance test, and the study was terminated by the sponsor.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.